Emerging In Vitro Diagnostic Technologies and Their Potential Applications
This new report from VPGMarketResearch.com provides assessments of emerging in vitro diagnostic technologies and their potential applications within the following market segments:
- Blood Typing, Grouping, and Screening
- Cancer Diagnostics
- Clinical Chemistry and Immunodiagnostics
- Coagulation Testing
- Hematology and Flow Cytometry
- Microbiology
- Molecular Diagnostics
- Artificial Intelligence
- Autologous Blood Transfusion/Freezing
- Automation
- Biosensors
- Blood Preservation
- Chromatography
- Chromogenic Substrates
- Chromosome Analysis
- Diagnostic Imaging
- Differential Light Scattering
- Dry Chemistry
- Flow Cytometry
- Gel Microdroplets
- Genetically Engineered Blood Components
- Immunoassays
- Information Technology
- Lasers
- Liposomes
- Microcomputers
- Microdrop Technology
- Microtitration Plates
- Molecular Diagnostics
- Monoclonal and Polyclonal Antibodies
- Robotics
- Synthetic Red Cell Substitutes
- Tandem Mass Spec
- Two Dimensional Gel Electrophoresis (2-DGE)
I. INTRODUCTION
II. EXECUTIVE SUMMARY
A. BUSINESS-AS-USUAL SCENARIO
B. ECONOMIC AUSTERITY SCENARIO
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
III. CONCLUSIONS AND RECOMMENDATIONS
IV.THE SCENARIOS
A. BUSINESS-AS-USUAL SCENARIO
1. Business Environment
a. Health Care Expenditures
b. Cost-Consciousness
c. Reimbursement
d. Industry Consolidation
e. Managed Care
PPOs
HMOs
f. Hospitals
g. Admissions
h. Length of Stay
i. Industry Diversification
j. Physician Demographics
k. Aging Population
Chronic Illnesses
Disease Incidence
Susceptibility to Iatrogenesis
Multiple Illness Cases
l. Laboratory Regulations
m. The FDA Reform
2. Outlook for the In Vitro Diagnostics Market
a. Government Regulations
b. Centralized Testing
Hospitals
Commercial Laboratories
Blood Banks
Public Health Laboratories
c. Decentralized Testing
Personal Testing
Physician Offices/Group Practices
Ancillary Hospital Locations
ERs
ORs
ICUs/CCUs
Cancer Clinics
Ambulatory Care Centers
Surgery Centers
Nursing Homes
Birth Centers
3. Strategic Implications
a. Testing Patterns
Test Utilization
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
4. Market Segments
a. Chemistry and Immunoassay
Introduction
Future Situation
b. Microbiology and Serology
Introduction
Future Situation
c. Hematology and Flow Cytometry
Introduction
Future Situation
d. Histology and Cytology
Introduction
Future Situation
e. Coagulation
Introduction
Future Situation
f. Urinalysis
Introduction
Future Situation
g. Blood Banking
Introduction
Future Situation
5.Technologies
a. Genomics
Introduction
Future Situation
b. Proteomics
Introduction
Future Situation
c. DNA Probes
Introduction
Future Situation
d. Biochips/Microarrays
Introduction
Future Situation
e. Monoclonal Antibodies
Introduction
Future Situation
f. Solid Phase Chemistry
Introduction
Future Situation
g. Biosensors
Introduction
Future Situation
h. Automation and Robotics
Introduction
Future Situation
i. Computer-Aided Diagnosis
Introduction
Future Situation
6.The New Marketplace
a. Purchasing Influences
b. Marketing Strategies
c. Joint Ventures, Mergers and Licensing
d. Import-Export
e. Potential Market Entrants
f. Who May Not Survive?
B. ECONOMIC AUSTERITY SCENARIO
1. Business Environment
a. Socio-Political Climate
Cost-Consciousness
Government Actions
Three-Tier System
Health Rationing
Voucher System
Health IRA
b. Hospital Closures
c. Hospital Utilization
d. Hospital Reorganization
e. Physician Regulations
f. Wellness Programs
g. Corporate Responses
h. Academic Research
2. Outlook for the In Vitro Diagnostics Market
a. Test Utilization
Ordering Practices
Documentation
Recertification
b.Technology Regulations
c. New Laboratory Ventures
d. Computers
e. Industrial Medicine
f. Insurance Companies
g. Test Volume and Market Size
3. Strategic Implications
a. Testing Patterns
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
b. Market Segments
Chemistry and Immunoassay
Microbiology and Serology
Hematology and Flow Cytometry
Histology and Cytology
Coagulation
Urinalysis
Blood Banking
c.Technologies
Genomics
Proteomics
DNA Probes
Biochips/Microarrays
Monoclonal Antibodies and Immunoassays
Automation and Robotics
Solid Phase Chemistry
Biosensors
Computer-Aided Diagnosis
d.The New Marketplace
Purchasing Influences
Marketing Strategies
Joint Ventures, Mergers and Licensing
Import-Export
Potential Market Entrants
Who May Not Survive?
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
1. Business Environment
a. Political/Regulatory Climate
b. R & D Funding
c. Industry-Government Relationship
d. Industry-University Ventures
e.Technological Environment
f. Testing Decentralization
g. Health Care Expenditures
h. Physician Population
i. Hospital Indicators
2. Outlook for the In Vitro Diagnostics Market
a. Overview
b. Genomics
c. Proteomics
d. DNA and RNA Probes
e. Biochips/Microarrays
f. Monoclonal Antibodies
g. Immunoassays
h. Information Technology
i. Laboratory Automation and Robotics
j. Solid Phase Chemistry
k. Biosensors
l. Holography
m. Pharmaceuticals
3. Strategic Implications
a.Testing Patterns
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
Test Volume and Market Size
b. Market Segments
Chemistry and Immunoassay
Microbiology and Serology
Hematology and Flow Cytometry
Histology and Cytology
Coagulation
Urinalysis
Blood Banking
c.The New Marketplace
Purchasing Influences
Marketing Strategies
Joint Ventures, Mergers and Licensing
Import-Export
Potential Market Entrants
Who May Not Survive?
V. APPENDICES: METHODOLOGY
A.The Delphi
B. Cross-Impact Analysis
C. Substitution Modeling
II. EXECUTIVE SUMMARY
A. BUSINESS-AS-USUAL SCENARIO
B. ECONOMIC AUSTERITY SCENARIO
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
III. CONCLUSIONS AND RECOMMENDATIONS
IV.THE SCENARIOS
A. BUSINESS-AS-USUAL SCENARIO
1. Business Environment
a. Health Care Expenditures
b. Cost-Consciousness
c. Reimbursement
d. Industry Consolidation
e. Managed Care
PPOs
HMOs
f. Hospitals
g. Admissions
h. Length of Stay
i. Industry Diversification
j. Physician Demographics
k. Aging Population
Chronic Illnesses
Disease Incidence
Susceptibility to Iatrogenesis
Multiple Illness Cases
l. Laboratory Regulations
m. The FDA Reform
2. Outlook for the In Vitro Diagnostics Market
a. Government Regulations
b. Centralized Testing
Hospitals
Commercial Laboratories
Blood Banks
Public Health Laboratories
c. Decentralized Testing
Personal Testing
Physician Offices/Group Practices
Ancillary Hospital Locations
ERs
ORs
ICUs/CCUs
Cancer Clinics
Ambulatory Care Centers
Surgery Centers
Nursing Homes
Birth Centers
3. Strategic Implications
a. Testing Patterns
Test Utilization
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
4. Market Segments
a. Chemistry and Immunoassay
Introduction
Future Situation
b. Microbiology and Serology
Introduction
Future Situation
c. Hematology and Flow Cytometry
Introduction
Future Situation
d. Histology and Cytology
Introduction
Future Situation
e. Coagulation
Introduction
Future Situation
f. Urinalysis
Introduction
Future Situation
g. Blood Banking
Introduction
Future Situation
5.Technologies
a. Genomics
Introduction
Future Situation
b. Proteomics
Introduction
Future Situation
c. DNA Probes
Introduction
Future Situation
d. Biochips/Microarrays
Introduction
Future Situation
e. Monoclonal Antibodies
Introduction
Future Situation
f. Solid Phase Chemistry
Introduction
Future Situation
g. Biosensors
Introduction
Future Situation
h. Automation and Robotics
Introduction
Future Situation
i. Computer-Aided Diagnosis
Introduction
Future Situation
6.The New Marketplace
a. Purchasing Influences
b. Marketing Strategies
c. Joint Ventures, Mergers and Licensing
d. Import-Export
e. Potential Market Entrants
f. Who May Not Survive?
B. ECONOMIC AUSTERITY SCENARIO
1. Business Environment
a. Socio-Political Climate
Cost-Consciousness
Government Actions
Three-Tier System
Health Rationing
Voucher System
Health IRA
b. Hospital Closures
c. Hospital Utilization
d. Hospital Reorganization
e. Physician Regulations
f. Wellness Programs
g. Corporate Responses
h. Academic Research
2. Outlook for the In Vitro Diagnostics Market
a. Test Utilization
Ordering Practices
Documentation
Recertification
b.Technology Regulations
c. New Laboratory Ventures
d. Computers
e. Industrial Medicine
f. Insurance Companies
g. Test Volume and Market Size
3. Strategic Implications
a. Testing Patterns
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
b. Market Segments
Chemistry and Immunoassay
Microbiology and Serology
Hematology and Flow Cytometry
Histology and Cytology
Coagulation
Urinalysis
Blood Banking
c.Technologies
Genomics
Proteomics
DNA Probes
Biochips/Microarrays
Monoclonal Antibodies and Immunoassays
Automation and Robotics
Solid Phase Chemistry
Biosensors
Computer-Aided Diagnosis
d.The New Marketplace
Purchasing Influences
Marketing Strategies
Joint Ventures, Mergers and Licensing
Import-Export
Potential Market Entrants
Who May Not Survive?
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
1. Business Environment
a. Political/Regulatory Climate
b. R & D Funding
c. Industry-Government Relationship
d. Industry-University Ventures
e.Technological Environment
f. Testing Decentralization
g. Health Care Expenditures
h. Physician Population
i. Hospital Indicators
2. Outlook for the In Vitro Diagnostics Market
a. Overview
b. Genomics
c. Proteomics
d. DNA and RNA Probes
e. Biochips/Microarrays
f. Monoclonal Antibodies
g. Immunoassays
h. Information Technology
i. Laboratory Automation and Robotics
j. Solid Phase Chemistry
k. Biosensors
l. Holography
m. Pharmaceuticals
3. Strategic Implications
a.Testing Patterns
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
Test Volume and Market Size
b. Market Segments
Chemistry and Immunoassay
Microbiology and Serology
Hematology and Flow Cytometry
Histology and Cytology
Coagulation
Urinalysis
Blood Banking
c.The New Marketplace
Purchasing Influences
Marketing Strategies
Joint Ventures, Mergers and Licensing
Import-Export
Potential Market Entrants
Who May Not Survive?
V. APPENDICES: METHODOLOGY
A.The Delphi
B. Cross-Impact Analysis
C. Substitution Modeling
LIST OF TABLES
Executive Summary Table I: Business-As-Usual Scenario, Growth Areas in Clinical Laboratory Testing
Executive Summary Table II: Economic Austerity Scenario, Growth Areas in Clinical Laboratory Testing
Executive Summary Table III: Technological Breakthroughs Scenario, Growth Areas in Clinical Laboratory Testing
Executive Summary Table IV: Market Size by Location
Executive Summary Table V: Market Size by Laboratory Discipline
Table-1: Business-As-Usual Scenario, Health Care Costs by Expenditure Type
Table-2: Business-As-Usual Scenario, HMO and PPO Enrollment
Table-3: Business-As-Usual Scenario, Selected Hospital Statistics
Table-4: Business-As-Usual Scenario, Total Population and Physician Demographics
Table-5: Business-As-Usual Scenario, Test Volume by Location
Table-6: Business-As-Usual Scenario, Test Distribution by Location
Table-7: Business-As-Usual Scenario, Market Size by Location
Table-8: Business-As-Usual Scenario, Typical Pre-Admission Tests
Table-9: Business-As-Usual Scenario, Test Volume by Laboratory Discipline
Table-10: Business-As-Usual Scenario, Market Size by Laboratory Discipline
Table-11: Economic Austerity Scenario, Selected Hospital Statistics
Table-12: Economic Austerity Scenario, HMO and PPO Enrollment
Table-13: Economic Austerity Scenario, Total Population and Physician Demographics
Table-14: Economic Austerity Scenario, Major Categories of Overutilized Tests
Table-15: Economic Austerity Scenario, Test Volume by Location
Table-16: Economic Austerity Scenario, Test Distribution by Location
Table-17: Economic Austerity Scenario, Market Size by Location
Table-18: Economic Austerity Scenario, Timing Requirements for Selected Laboratory Tests
Table-19: Economic Austerity Scenario, Test Volume by Laboratory Discipline
Table-20: Economic Austerity Scenario, Market Size by Laboratory Discipline
Table-21: Technological Breakthroughs Scenario, HMO and PPO Enrollment
Table-22: Technological Breakthroughs Scenario, Total Population and Physician Demographics
Table-23: Technological Breakthroughs Scenario, Selected Hospital Statistics
Table-24: Technological Breakthroughs Scenario, Test Volume by Location
Table-25: Technological Breakthroughs Scenario, Test Distribution by Location
Table-26: Technological Breakthroughs Scenario, Market Size by Location
Table-27: Technological Breakthroughs Scenario, Test Volume by Laboratory Discipline
Table-28: Technological Breakthroughs Scenario, Market Size by Laboratory Discipline
Executive Summary Table I: Business-As-Usual Scenario, Growth Areas in Clinical Laboratory Testing
Executive Summary Table II: Economic Austerity Scenario, Growth Areas in Clinical Laboratory Testing
Executive Summary Table III: Technological Breakthroughs Scenario, Growth Areas in Clinical Laboratory Testing
Executive Summary Table IV: Market Size by Location
Executive Summary Table V: Market Size by Laboratory Discipline
Table-1: Business-As-Usual Scenario, Health Care Costs by Expenditure Type
Table-2: Business-As-Usual Scenario, HMO and PPO Enrollment
Table-3: Business-As-Usual Scenario, Selected Hospital Statistics
Table-4: Business-As-Usual Scenario, Total Population and Physician Demographics
Table-5: Business-As-Usual Scenario, Test Volume by Location
Table-6: Business-As-Usual Scenario, Test Distribution by Location
Table-7: Business-As-Usual Scenario, Market Size by Location
Table-8: Business-As-Usual Scenario, Typical Pre-Admission Tests
Table-9: Business-As-Usual Scenario, Test Volume by Laboratory Discipline
Table-10: Business-As-Usual Scenario, Market Size by Laboratory Discipline
Table-11: Economic Austerity Scenario, Selected Hospital Statistics
Table-12: Economic Austerity Scenario, HMO and PPO Enrollment
Table-13: Economic Austerity Scenario, Total Population and Physician Demographics
Table-14: Economic Austerity Scenario, Major Categories of Overutilized Tests
Table-15: Economic Austerity Scenario, Test Volume by Location
Table-16: Economic Austerity Scenario, Test Distribution by Location
Table-17: Economic Austerity Scenario, Market Size by Location
Table-18: Economic Austerity Scenario, Timing Requirements for Selected Laboratory Tests
Table-19: Economic Austerity Scenario, Test Volume by Laboratory Discipline
Table-20: Economic Austerity Scenario, Market Size by Laboratory Discipline
Table-21: Technological Breakthroughs Scenario, HMO and PPO Enrollment
Table-22: Technological Breakthroughs Scenario, Total Population and Physician Demographics
Table-23: Technological Breakthroughs Scenario, Selected Hospital Statistics
Table-24: Technological Breakthroughs Scenario, Test Volume by Location
Table-25: Technological Breakthroughs Scenario, Test Distribution by Location
Table-26: Technological Breakthroughs Scenario, Market Size by Location
Table-27: Technological Breakthroughs Scenario, Test Volume by Laboratory Discipline
Table-28: Technological Breakthroughs Scenario, Market Size by Laboratory Discipline
